X
1. 32384-65-9
2. (3r,4s,5r,6r)-3,4,5-tris(trimethylsilyloxy)-6-((trimethylsilyloxy)methyl)tetrahydro-2h-pyran-2-one
3. (3r,4s,5r,6r)-3,4,5-tris(trimethylsilyloxy)-6-(trimethylsilyloxymethyl)oxan-2-one
4. 2,3,4,6-tetrakis-o-trimethylsilyl-d-gluconolactone
5. 2,3,4,6-tetrakis-o-(trimethylsilyl)-d-glucono-1,5-lactone
6. (3r,4s,5r,6r)-3,4,5-tris(trimethylsilyloxy)-6-((trimethylsilyloxy)methyl)-tetrahydropyran-2-one
7. 2,3,4,6-tetra-o-(trimethylsilyl)-d-glucono-delta-lactone
8. Mfcd22665922
9. Gluconic Acid Lactone, Tms # 1
10. Ec 608-732-8
11. Schembl18174
12. Amy287
13. Canagliflozin Related Impurity 9
14. 2,3,4,6-tetra-o-(trimethylsilyl)-d-glucono-1,5-lactone
15. Dtxsid30451107
16. (3r,4s,5r,6r)-3,4,5-tris[(trimethylsilyl)oxy]-6-{[(trimethylsilyl)oxy]methyl}oxan-2-one
17. Cs-m2269
18. Akos022174947
19. Zinc169747786
20. Ds-7487
21. (3r,4s,5r,6r)-3,4,5-tris(trimethylsilyloxy)-6-(trimethylsilyloxymethyl)tetrahydropyran-2-one
22. (3r,4s,5r,6r)-3,4,5-tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-on
23. (3r,4s,5r,6r)-3,4,5-tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one
24. (3r,4s,5r,6r)-3,4,5-tris[(trimethylsilyl)oxy]-6-{[(trimethylsilyl)oxy]methyl}oxan-2-one (non-preferred Name)
25. Ac-27653
26. A855898
27. 2,3,4,6-tetrakis-o-trimethyl Silyl-d-gluconolactone
28. Not Available;2,3,4,6-tetra-o-(trimethylsilyl)-d-glucono-delta-lactone
29. (3r,4 S,5r,6r)-3,4,5-tris(trimethylsilyloxy)-6-trimethylsilyloxymethyltetrahydropyran-2-one
30. (3r,4s,5r,6r)-3,4,5-tri((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetra Hydro-2h-pyran-2-one
31. (3r,4s,5r,6r)-3,4,5-tri((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2h-pyran-2-one
32. (3r,4s,5r,6r)-3,4,5-tris -(trimethylsilyloxy)-6-((trimethylsilyloxy)methyl)-tetrahydropyran-2-one
33. (3r,4s,5r,6r)-3,4,5-tris-(trimethylsilyloxy)-6-((trimethylsilyloxy)methyl)-tetrahydropyran-2-one
| Molecular Weight | 466.9 g/mol |
|---|---|
| Molecular Formula | C18H42O6Si4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 9 |
| Exact Mass | 466.20584519 g/mol |
| Monoisotopic Mass | 466.20584519 g/mol |
| Topological Polar Surface Area | 63.2 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 530 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
List of Suppliers
Iran Expo
Not Confirmed
Contact SupplierNote: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Iran Expo
Not Confirmed
Contact SupplierIran Expo
Not Confirmed
Contact SupplierIran Expo
Not Confirmed
Contact Supplier
Iran Expo
Not Confirmed
Contact SupplierIran Expo
Not Confirmed
Contact SupplierIran Expo
Not Confirmed
Contact SupplierIran Expo
Not Confirmed
Contact SupplierIran Expo
Not Confirmed
Contact Supplier
Iran Expo
Not Confirmed
Contact Supplier
Market Place
Soujanya Life Sciences makes API & intermediates for various therapeutic categories including Antidiabetic, Anti-Hypertensive, etc.
